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Abstract
Background: Hematopoietic stem cell transplantation (HSCT) is the only curative treatment available to severe
thalassemic patients. The treatment, however, is very costly, particularly in the context of low and middle income
countries, and no studies have been carried out to explore its economic justifiability. This study aimed to estimate
the cost-utility of HSCT compared with blood transfusions combined with iron chelating therapy (BT-ICT) for severe
thalassemia in Thailand, and to investigate the affordability of HSCT using a budget impact analysis.
Methods: A Markov model was used to estimate the relevant costs and health outcomes over the patients’
lifetimes taking a societal perspective as recommended by Thailand’s health technology assessment guidelines. All
future costs and outcomes were discounted at a rate of 3% per annum. Primary outcomes of interest were lifetime
costs, quality adjusted life years (QALYs) gained, and the incremental cost-effectiveness ratio (ICER) in Thai baht
(THB) per QALY gained.
Results: Compared to BT-ICT, the incremental cost-effectiveness ratio increased with patient age from 80,700 to
183,000 THB per QALY gained for related HSCT and 209,000 to 953,000 THB per QALY gained for unrelated HSCT
among patients aged 1 to 15 years (US$1= 34 THB). The governmental budget impact analysis showed that
providing 200 related HSCT to patients aged 1 to 10 years, in accordance with the current infrastructure limitations,
would initially require approximately 90 million additional THB per year.
Conclusions: At a societal willingness to pay of 100,000 THB per QALY gained, related HSCT was likely to be a
cost-effective and affordable treatment for young children with severe thalassemia in Thailand.
Background
Thalassemia is the most common gene-related hemato-
logical disease in Thailand. With a Thai population of
65 million, approximately 40% carry thalassemia traits
and about 1% manifest the disease [1]. The incidence of
severe thalassemia (i.e. Hb Bart’sh y d r o p sf e t a l i s ,b-tha-
lassemia, and b-thalassemia/Hb E) is estimated at 4,253
patients per year [1]. Generally patients with severe tha-
lassemia present with anemia at the first year of life.
The provision of regular blood transfusion (BT) is stan-
dard practice for the treatment of severe thalassemia.
Without ongoing BT, these individuals would have an
expected life-span of only a few years. However, provi-
sion of BT is hampered by a shortage of blood dona-
tions, as well as the high cost of blood screening in
order to reduce the residual risk of transmission of
blood-borne viruses, including hepatitis and human
immunodeficiency virus/acquired immunodeficiency
syndrome (HIV/AIDS) [2]. Moreover, BT given over a
long period of time can result in iron-overload causing
heart failure and damage to other organs associated
with high mortality. In order to reduce iron
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administered subcutaneously for 8 to 12 hours per day,
5 to 7 days per week. Effective provision of ICT is often
compromised by poor compliance as the process itself
can have a detrimental effect on quality of life (QoL),
especially amongst children [3,4].
Currently, hematopoietic stem cell transplantation
(HSCT) is the only curative treatment available to severe
thalassemic patients. Hematopoietic stem cells are
usually extracted from bone marrow, peripheral blood,
and umbilical cord blood. An allogeneic HSCT patient
can obtain stem cells from a healthy human leukocyte
antigen (HLA)-matched donor, being either a patient’s
relative (i.e. related HSCT) or from non-related donors
(i.e. unrelated HSCT). HLA is determined by conven-
tional serologic typing for class I and II antigen. DNA
typing with high-resolution sequence-specific oligonu-
cleotide probes for class I and II loci is undertaken for
patients with matched and mismatched HLA-related or
mismatched HLA-unrelated donors. Sibling donors are
considered ideal as they can inherit identical HLA
genes, reducing the probability of graft rejection and
other complications. The formula for calculating the
chances of a particular person having an HLA-matched
sibling is 1 - (0.75)
n ,w h e r en denotes the total number
of siblings [5]. The average Thai family has two chil-
dren; therefore only 1 in 4 patients are likely to have an
HLA-matched sibling donor [6], while only 3 out of 4 of
these potential sibling-donors would themselves be
without thalassemia. Thus the proportion of thalassemic
patients that would have an HLA-matched sibling donor
is approximately 19%. The remainder of the population
must rely on unrelated donors. At present there is no
local database in place for the identification of such
donors, while reliance on foreign databases implies
reduced donor availability and an increase in costs.
HSCT procedures are conditioning regimens to eradi-
cate disease and facilitate persistent engraftment [7].
G r a f tv e r s u sh o s td i s e a s e( G V H D )p r o p h y l a x i si sp e r -
formed to prevent major complications related to severe
immune incompetence. All HSCT patients are treated in
positive-pressure isolation rooms and receive antibiotics
for prevention of Pneumocystis carinii pneumonia, Cyto-
megalovirus, and Ebstein-Barr virus. The criteria of
engraftment are an absolute neutrophil count more than
0.5 × 109/L within three consecutive days or a platelet
count more than 20 × 109/L without transfusion within
seven consecutive days [7-9]. If the patients have
engraftment failure after receiving HSCT, a second
round of HSCT may be provided to prevent thalassemia
recurrence or irreversible aplasia.
As evident, HSCT is a resource-intense procedure
requiring high financial expenditure especially at the
first year of treatment. Moreover, patients receiving
H S C Tm a ye x p e r i e n c ep o o rq u a l i t yo fl i f ed u et oi t s
toxicity and complications. HSCT, however, is the only
treatment to cure thalassemia at present, providing
patients with longer life expectancy and potentially nor-
mal quality of life [6].
In Thailand, healthcare coverage for the provision of
HSCT differs amongst the three health insurance
schemes. HSCT is provided with full coverage to thalas-
semic patients who are government employees and their
dependents enrolled under the Civil Servant Medical
Benefit Scheme (9% of the Thai population) as well as
employees enrolled under the Social Security Scheme
(11% of the population). Provision of HSCT has not yet
been included in the benefit package of the Universal
Coverage (UC) scheme that applies to approximately
80% of the Thai population and is managed by the
National Health Security Office (NHSO) [10].
An economic evaluation of HSCT for severe thalasse-
mic patients was requested by the NHSO through a
topic selection process facilitated by the Health Inter-
vention and Technology Assessment Program (HITAP)
[11], the institution responsible for appraising a wide
range of health technologies including pharmaceuticals,
medical devices, interventions, individual and commu-
nity health promotion and prevention interventions.
HITAP sent out an official letter dated December 27th,
2006 inviting public health agencies at the national level
to submit their lists of interventions which they consid-
ered to require assessment. The representatives of these
fifteen agencies were also invited to participate in a
workshop which aimed at prioritizing the proposed
health interventions in order to select the top ten most
important items for the HITAP assessment process. The
economic evaluation of HSCT was ranked as one out of
five selected topics in 2007. This cost-utility analysis,
therefore, was performed to evaluate and compare the
costs and health outcomes for related and unrelated
HSCT compared with BT-ICT.
The comparison of related HSCT and BT-ICT is
aimed at those patients that have HLA-matched siblings.
For the majority of the population however, for whom a
matched donor is not readily available, the comparison
is between unrelated HSCT and BT-ICT. A preliminary
analysis based on the literature showed that when both
interventions are available, related HSCT always domi-
nated unrelated HSCT, since in addition to higher costs,
the outcome of unrelated HSCT is often compromised
by an increase in transplant-related complications
including early and late toxicity, mortality and rejection
[6,7,11,12]. As a result, there is no head-to-head com-
parison of related and unrelated HSCT in this analysis,
as it is clear that where related HSCT is viable, this
would be the preferred option. In instances where
HSCT was found to be cost-effective, the impact of
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get was estimated.
Methods
The lifetime costs and health outcomes for severe tha-
lassemic patients aged 1 to 28 years receiving either
HSCT or BT-ICT were compared taking a societal per-
spective as recommended by the Thailand’s health tech-
nology assessment guidelines [13]. All future costs and
outcomes were discounted at a rate of 3% per annum
[14]. Primary outcomes of interest were lifetime costs,
quality adjusted life years (QALYs) gained, and the
incremental cost-effectiveness ratio (ICER) in Thai baht
(THB) per QALY gained. Based on the statement of the
Subcommittee for Development of the National List of
Essential Drugs and the Subcommittee for Development
of the Health Benefit Package and Service Delivery of
the NHSO in 2007, the societal willingness to pay
(WTP) threshold for a QALY gained for the adoption of
health interventions is between 100,000 THB (6,000 PPP
$) to 300,000 THB (18,000 PPP$), approximating one to
three times per capita Gross Domestic Product (GDP)
[ 1 5 ] .T h e s ev a l u e sa r ei na c c o r d a n c ew i t ht h er e c o m -
mendations of the Commission on Macroeconomics and
Health, World Health Organization, suggesting that
health technologies with ICERs below the per capita
GDP are considered very cost-effective, those between
one and three times per capita GDP being cost-effective,
while ICERs above three times per capita GDP indicate
that a health technology is not cost-effective [16].
Economic model
Figure 1 illustrates the structure of a Markov model
used to estimate the relevant costs and health outcomes.
The time horizon used is the patients’ estimated life-
times and the length of each cycle is one year. Two
mutually exclusive treatment options, related and unre-
lated HSCT, were compared with BT-ICT (i.e. desfer-
rioxamine–DFO), which is standard practice and
currently covered under the UC scheme.
The health states of both related and unrelated HSCT
patients consisted of five states with different costs and
QoL scores as follows: (i) the first year of HSCT where
patients had the highest costs and worst QoL; (ii) the
second year of HSCT, where patients had higher costs
due to follow up visits and immunosuppressive therapy;
(iii) following years after successful HSCT where QoL
approximates that of the healthy population and costs
were vastly reduced; (iv) HSCT failure resulting in a
switch to BT-ICT; and (v) death. Blood transfusions-
dependent patients had two health states (i.e. BT-ICT,
characterized by low QoL, and the costs of ongoing care
and death). The arrows represent the possible transi-
tions from one state to another. Treatment complica-
tions were included within all health states as they
typically took far less than one year to resolve.
Figure 1 Schematic diagram of the Markov model. Each thalassemic patient has two treatment options (i.e. HSCT and BT-ICT). The Markov
model consists of five health states and patients receiving HSCT can transition through each of these health states whereas BT-ICT patients can
be in either alive BT-ICT state or death state. The cycle length is one year with a 99-year time horizon. HSCT: hematopoietic stem cell
transplantation; BT-ICT: blood transfusion combined with subcutaneous iron chelating therapy.
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comes over a 99-year period to cover the maximum
expected lifetime horizon. Based on clinical practice,
the following assumptions were used in the model.
First, all severe thalassemic patients in this study were
assumed to be treated with blood transfusions during
the first year of life. Second, ICT was administered via
subcutaneous infusion only. Finally, probability of
death in HSCT failure patients switching to blood
transfusions was similar to that in blood transfusion
patients that did not undergo HSCT. All transition
probabilities, costs and outcomes variables are shown
in Table 1.
Cost variables
All costs were converted and reported in 2008 THB (US
$1= 34 THB) using the consumer price index (CPI)
[17]. For international comparison, costs were converted
to international dollars using a purchasing power parity
(PPP) exchange rate (1 PPP$(2008) = 15.954 THB) [18].
Direct medical costs were obtained from two data
sources. First, the costs for blood transfusion-dependent
Table 1 Input parameters used in the model
Parameters Distribution Mean SE References and type of data
Yearly discount rate (%)
Costs (range) 3.00 (0-6.00) - [14]
Outcomes (range) 3.00 (0-6.00) - [14]
Transition probabilities
BT-ICT
Annual probability of death at age 0-1 Beta 0.010 - [23]
Annual probability of death at age 2-5 Beta 0.003 - [23]
Annual probability of death at age 6-10 Beta 0.002 - [23]
Annual probability of death at age 11-15 Beta 0.010 - [23]
Annual probability of death at age 16-20 Beta 0.025 - [23]
Annual probability of death at age 21-30 Beta 0.015 - [22]
Annual probability of death at age 31 and more Beta 0.345 - [21]
HSCT
Parametric survival: death
Constant for baseline hazard Lognormal -8.07 2.00 Cohort
Age coefficient for baseline hazard Lognormal 0.16 0.06 Cohort
Ancillary parameter in Weibull distribution Lognormal -0.61 0.41 Cohort
Parametric survival: failure
Constant for baseline hazard Lognormal -7.18 1.55 Cohort
Type of HSCT coefficient for baseline hazard Lognormal 2.60 1.08 Cohort
Ancillary parameter in Weibull distribution Lognormal -0.74 0.34 Cohort
Resource cost parameters (THB)
Total direct medical cost of related HSCT in the 1
st year Gamma 491,985 50,288 Hospital database
Total direct medical cost of related HSCT in the 2
nd year Gamma 42,694 15,535 Hospital database
Total direct medical cost of related HSCT in the following years Gamma 11,638 3,240 Hospital database
Total direct medical cost of unrelated HSCT at the 1
st year Gamma 735,839 183,560 Hospital database
Total direct medical cost of unrelated HSCT at the 2
nd year Gamma 45,840 20,094 Hospital database
Total direct medical cost of unrelated HSCT in the following years Gamma 6,385 1,037 Hospital database
Total direct medical cost of BT-ICT per year Gamma 35,788 4,156 [4]
Total direct non-medical cost of HSCT at the 1
st and 2
nd year Gamma 259,994 95,535 Survey
Total direct non-medical cost of BT-ICT and the following year of HSCT Gamma 37,384 7,040 Survey
Total productivity loss of HSCT in the 1
st and 2
nd year Gamma 77,468 70,464 Survey
Total productivity loss of BT-ICT and the following years of HSCT Gamma 19,171 6,692 Survey
Utility parameters
Utility of BT-ICT patients Beta 0.61 0.16 [24,25]
Utility of HSCT patients in first and second year Beta 0.61 0.16 [24,25]
Utility of HSCT patients from third year on Beta 0.93 0.05 [26]
BT-ICT: blood transfusion combined with subcutaneous iron chelating therapy; HSCT: hematopoietic stem cell transplantation; and THB: Thai baht in 2008 value.
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arus et al [4]. The study population consisted of 124
severe thalassemia patients. Mean direct medical costs
per year were 35,788 THB (SE = 4,156). The costs of
patients receiving HSCT were retrieved from a hospital
database at a teaching hospital between 1989 and 2007.
The charges per patient per year were adjusted using a
cost-to-charge ratio of 0.8 [19].
Both direct non-medical and indirect costs were col-
lected by interviewing severe thalassemic patients and
their caregivers at the teaching hospital after informed
consent was obtained. Ethical approval for this study
was granted by the Committee on Human Rights
Related to Research Involving Human Subjects, Mahi-
dol University for cost and clinical data collection.
Two HSCT patients and twenty eight BT-ICT patients
were interviewed by questionnaire. Mean age was 18
years (Range = 1-47 years). Direct non-medical costs
including costs of transportation, meals, accommoda-
tion, facilities, and informal care were 37,384 THB (SE
= 7,040) for BT-ICT patients and 259,994 THB (SE =
9 5 , 5 3 5 )a tt h ef i r s ta n ds e c o n dy e a ro fH S C T[ 1 3 ] .
Indirect costs referred to productivity losses due to
sick leave and were estimated at 19,171 THB (SE =
6,692) for BT-ICT and 77,468 THB (SE = 70,464) at
the first and second year of HSCT [13]. Since there
were no data available on direct non-medical and
indirect costs of HSCT patients after the first two
years of treatment, it was assumed that these costs of
HSCT patients were similar to those receiving BT-ICT
in the following years. Resource cost parameters are
presented in Table 1.
Clinical variables
Transitional probabilities or tp(u) (i.e. transition to fail-
ure and transition to death) were required for the Mar-
kov model to simulate patients with different ages when
starting HSCT. First, patient-level time to event data
with clinical variables such as survival time, demo-
graphic characteristics, and patient status (alive/dead)
were collected from the medical records of 67 patients
receiving either related (44) or unrelated HSCT (23) at
the teaching hospital between 1989 and 2007. There
were 26 cases with b- thalassemia and 41 cases with b-
thalassemia/HbE. Mean age was 8 years (Range = 1-28
years). These patients were classified as moderate to
high risk according to Lucarelli or Pesaro classification
[6]. Second, a parametric survival-time model using
Weibull regression was applied in order to yield H(t)
which is the cumulative hazard, l (lambda) which is the
scale parameter, and g (gamma) which is the shape para-
meter based on the below survival function (see equa-
tions 1-3). The survival function, S(t) which describes
the probability of survival as a function of patient age at
the start of HSCT is [20]:
St H t () =− {} exp ( )
where H(t) is the cumulative hazard; l (lambda) is the
scale parameter; t is time in days; and ancillary or g
(gamma) is the shape parameter that describes the
instantaneous hazard rate h(t), which increases with age
at the start of HSCT if g is more than one. The influ-
ence of patient age at the start of HSCT and whether
they had a related or unrelated donor on mortality and
treatment failure was assessed and found that l for fail-
u r ee v e n td e p e n d e do nt h et y p eo fd o n o ra n dl for
death event depended on the age covariate as illustrated
in the following formula:
Ht t () = 

Last, the transitional probability of the event of inter-
est during the cycle, tp(u), is calculated using H(t-u) and
H(t) as well as being estimated from the following for-
mula (where u is the cycle length of the model):
 =+ exp constant age coefficient age at the start of treatmen *t t () {}
In addition, for patients receiving BT-ICT, the transi-
tion probabilities converted to annual probabilities of
death were derived from available cohort studies
[21-23]. Based on the cohort of 67 patients, no one
received HSCT more than twice. Therefore, in the
model it was assumed that if the HSCT patients had
failed twice, patients would receive BT-ICT for the rest
of their lives.
Quality of life variables
Utility measures for patients’ quality of life were
obtained from a systematic review of electronic data-
bases. Two databases (PubMed and Center of Reviews
and Dissemination) were searched using the following
keywords: ("Quality of Life"[Mesh] OR “Quality-
Adjusted Life Years"[Mesh] OR “Models, Economic"[-
Mesh]) AND ("Thalassemia"[Mesh] OR “beta-Thalasse-
mia"[Mesh] OR thalassaemia) and (thalassemia OR
thalassaemia) AND “quality of life”, respectively. Inclu-
sion criteria were where QoL is presented in a utility
index (0=death and 1=full health) and measured by time
trade-off (TTO), standard gamble (SG), or EQ-5D
instruments. Two eligible studies reported that the
mean utility indices of patients receiving BT-ICT were
0.61 and 0.66 [24,25]. A Bayesian random effects meta-
analysis using WinBUGS1.4 (Medical Research Council
and Imperial College of Science, Technology and
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pooled estimate of 0.61 (SE = 0.16). No studies relating
to the QoL of severe thalassemic patients receiving
HSCT were identified, therefore the utility of thalasse-
mic patients receiving HSCT at the first and second
years was assumed to be the same as that of thalassemic
patients receiving BT-ICT for the worst case analysis.
The utility of HSCT patients in the subsequent years
was derived from the utility of HSCT patients in other
diseases following HSCT (i.e. acute myeloid leukemia,
multiple myeloma, non-Hodgkin lymphoma, and Hodg-
kin lymphoma) equal to 0.93 (SE 0.05) [26].
Uncertainty analysis
One-way sensitivity analysis was performed to examine
the uncertainty surrounding each parameter individually
and results were presented using a tornado diagram. In
addition, a probabilistic sensitivity analysis (PSA) was
conducted to examine the effect of all parameter uncer-
tainty simultaneously using a second order Monte Carlo
simulation performed by Microsoft Excel 2003 (Micro-
soft Corp., Redmond, WA) [20]. Probability distributions
were assigned as follows [27]: (i) beta-distributions were
assigned where parameter values ranged between zero
and one, such as in probability and utility parameters,
(ii) gamma-distributions were specified when parameter
values were above zero and positively skewed, such as in
costs, and (iii) a log-normal distribution was used for
survival parameters. The mean, SE, and distribution of
input parameters used in the model are shown in Table
1. A Monte Carlo simulation was run for 1,000 itera-
tions to yield a range of probable values for total costs,
health outcomes, and ICERs. In addition, the maximum
expected net monetary benefit (NMB) was calculated for
each ceiling ratio value (the value society would be
WTP for a QALY gained). Results of the PSA were pre-
sented as cost-effectiveness acceptability curves.
Budget impact analysis
A Markov-based budget impact model was developed to
evaluate direct medical costs for severe thalassemic
patients based on a governmental perspective over 15
fiscal years. The model compared direct medical costs
for BT-ICT to those of HSCT, where this was found to
be a cost-effective option at a ceiling ratio of 100,000
THB per QALY gained [15], approximating the Thai
GDP per capita [18]. The actual number of additional
HSCT procedures that could be carried out in practice
is currently restricted to approximately 200 thalassemic
patients as there are only four university hospitals that
have the necessary specialists and suitable infrastructure
to carry out HSCT (Suradej Hongeng, Vijj Kasemsup,
Ramathibodi University Hospital, oral communication,
March 24, 2009). Thus, the actual budget impact on the
universal health insurance scheme was estimated for the
maximum expected number of severe thalassemic
patients that could receive HSCT at the four teaching
hospitals, rather than the incidence of severe
thalassemia.
Results
Cost-utility analysis
Average lifetime costs and QALYs gained of related
HSCT and unrelated HSCT compared with BT-ICT
classified by patient age at the start of treatment are
shown in Figure 2. The lifetime costs were the highest
for unrelated HSCT, followed by related HSCT, while
BT-ICT incurred the lowest cost across all age groups.
Both related and unrelated HSCT yielded more QALYs
than BT-ICT amongst patients aged 1 to 19 and 1 to 17
years, respectively, after which BT-ICT yielded more
QALYs.
When the costs and QALYs of related HSCT and
unrelated HSCT were compared, it was confirmed that
related HSCT always dominated unrelated HSCT due
primarily to an increase in transplant-related complica-
tions including early and late toxicity, mortality and
rejection [6,7,11,12]. Thus, for patients who had HLA-
matched siblings the ICER of related HSCT was com-
pared with that of BT-ICT (Table 2), while for those
who did not have an HLA-matched sibling, the ICER of
unrelated HSCT was compared with that of BT-ICT
(Table 3), with no direct comparison required between
related and unrelated HSCT. The ICERs of both related
and unrelated HSCT increased with patient age up to
the age of 20 and 18 years, respectively, at which point
they were both dominated by BT-ICT which incurred
lower cost and yielded more QALYs. The ICERs of
related HSCT for patients aged 1 to 19 years were
80,700 to 574,000 THB per QALY gained, and the
ICERs of unrelated HSCT for patients aged 1 to 17
years were 209,000 to 3,270,000 THB per QALY gained.
Uncertainty analysis
Figure 3 shows a tornado diagram presenting the results
of one-way sensitivity analyses in the case of patients at
1 year of age receiving related HSCT. It was found that
when altering the value of each parameter within plausi-
ble ranges, the ICER per QALY gained was most sensi-
tive to changes in the utility of blood transfusion
patients, followed by changes in the discount rate to 0%
and 6% per annum, direct non-medical costs of related
HSCT, utility of HSCT patients, and direct medical
costs. It is noteworthy that the ICER was less sensitive
to changes in the transition probabilities of both related
HSCT and BT-ICT.
Figure 4 illustrates the cost-effectiveness acceptability
curves based on the PSA results for related HSCT
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vertical dashed lines show the WTP thresholds of 100,000
and 300,000 THB per QALY gained. At a WTP threshold
of 100,000 THB per QALY gained, the probabilities that
related HSCT would be cost-effective were 81%, 59%, 29%,
and 18% for patients aged 1, 10, 15, and 17 years, respec-
tively. At a WTP threshold of 300,000 THB per QALY
gained, the probabilities that related HSCT would be cost-
effective were 96%, 88%, 70%, and 60% for patient aged 1,
10, 15, and 17 years, respectively.
Figure 5 shows the cost-effectiveness acceptability
curves based on the PSA results for unrelated HSCT
classified by patient age at the beginning of treatment.
At a WTP threshold of 100,000 THB per QALY gained,
unrelated HSCT would not be cost-effective when com-
pared with BT-ICT, as the ICER is higher than the ceil-
ing ratio. At a WTP threshold of 300,000 THB per
QALY gained, the probabilities that unrelated HSCT
would be cost-effective were 68% and 54% for patient
aged 1 and 10 years, respectively.
Budget impact analysis
The budget impact analysis shows how the implementa-
tion of related HSCT in patients for whom it was found
to be cost-effective at a WTP threshold of 100,000 THB
per QALY gained would impact future expenditure [15],
should the NHSO decide to include HSCT in the bene-
fit package of the UC scheme. The number of treat-
ments for which this is calculated is 200 thalassemic
patients per year (Suradej Hongeng, Vijj Kasemsup,
Ramathibodi University Hospital, oral communication,
March 24, 2009), due to infrastructure restrictions, and
their impact on the government budget during fiscal
years 2008 to 2022 is presented in Table 4.
The costs shown in the table related to a cohort of
patients that increases by 200 each year (minus
Figure 2 Lifetime costs and quality adjusted life years of treatment. (A) The lifetime costs and (B) Quality adjusted life years of treatment
options of severe thalassemia classified by patient age at the start of treatments. THB: Thai baht (in 2008 value); BT-ICT: blood transfusion
combined with subcutaneous iron chelating therapy; and HSCT: hematopoietic stem cell transplantation.
Leelahavarong et al. BMC Health Services Research 2010, 10:209
http://www.biomedcentral.com/1472-6963/10/209
Page 7 of 12fatalities), where in the BT-ICT column the cost consists
of their ongoing treatments, while in the HSCT column
the costs comprise of 200 treatments each year, the cost
of BT-ICT for treatment failures, and the cost of follow-
up procedures. It should be noted that the follow up
costs were significantly reduced over time owing to the
effect of discounting and reduction of costs of long-
term care for HSCT patients. The rightmost column
shows the actual impact of the government budget. Not-
withstanding future possible changes in HSCT and BT-
ICT costs, as the number of patients receiving BT-ICT
increases continuously the difference in cost gradually
decreases and over a longer time span would eventually
become negative (i.e. HSCT would become the more
affordable option).
Discussion
This study is the first to compare the cost-effectiveness
of related and unrelated HSCT to BT-ICT for severe
thalassemic patients. Based on the WTP threshold of
100,000 THB per QALY gained [15,28], this analysis
shows that provision of HSCT to severe thalassemic
patients with related or sibling donors was likely to be
cost-effective only when provided to patients aged up to
10 years. Although we found that providing related
HSCT to the youngest patients yields the maximum
benefit, there are ethical and practical issues that require
further consideration. For example, the availability of a
sibling donor for a one year old patient will be more
restricted than those for ten year old patients, as it is
more likely that the 10 year old patients would have
healthy siblings (having both elder and younger siblings
that could act as donors). The majority of severe thalas-
semic patients, however, do not have the option of
related HSCT, since most of them are either single chil-
dren or they have no HLA-matched non-thalassemic
relative or sibling donor. For these patients unrelated
HSCT was the only alternative to BT-ICT. Although at
a WTP of 300,000 THB per QALY gained unrelated
HSCT was likely to be considered a cost-effective option
f o rp a t i e n t sa g e du pt o1 0y e a r s ,i tm i g h tn o ty e tb e
appropriate within the Thai context, where the identifi-
cation procedure for HLA-matched donors is very lim-
ited and expensive, as donors have to be identified from
foreign sources such as the Tzu chi Taiwan Marrow
Donor Registry [8]. Furthermore, if unrelated HSCT
procedure failed, the patients would be more likely to
switch to standard therapy (BT-ICT) in the absence of
another donor. The provision of HSCT only to younger
patients for whom sibling donors are available, however,
raises a substantial equity concern in that patients with-
out a sibling donor or over the age of 10 would not be
eligible to benefit from a potentially life-saving
treatment.
The governmental budget impact demonstrated that
the provision of related HSCT to patients for whom
HSCT was found to be cost-effective could eventually
result in lower government expenditure than ongoing
BT-ICT. The budget impact analysis took a very practi-
cal perspective in calculating the costs for only 200
patients per year in accordance with the current
Table 2 ICER of related HSCT compared to BT-ICT,
classified by patient age
Age
(year)
Incremental
cost
Incremental
QALY
ICERs of related
HSCT
compared to BT-ICT
million THB QALY gained THB per QALY
gained*
1 0.81 10.00 80,700
5 0.78 8.96 86,800
10 0.72 7.02 103,000
15 0.61 3.32 183,000
17 0.55 2.14 257,000
18 0.55 1.78 308,000
19 0.48 0.84 574,000
20 0.40 -0.20 Dominated
§
25 0.30 -2.05 Dominated
§
28 0.31 -2.17 Dominated
§
ICER: incremental cost-effectiveness ratio; HSCT: hematopoietic stem cell
transplantation; BT-ICT: blood transfusion combined with subcutaneous iron
chelating therapy; THB: Thai baht (in 2008 value); and QALY: quality adjusted
life year.
*ICERs are rounded up to nearest 1,000 THB.
§Negative ICER due to higher effectiveness and lower costs of BT-ICT
compared with HSCT.
Table 3 ICER of unrelated HSCT compared to BT-ICT,
classified by patient age
Age
(year)
Incremental
cost
Incremental
QALY
ICER of unrelated
HSCT
compared to BT-ICT
million THB QALY gained THB per QALY
gained*
1 0.96 4.57 209,000
5 0.94 4.16 225,000
10 0.91 3.05 297,000
15 0.84 0.87 953,000
17 0.80 0.26 3,270,000
18 0.78 -0.01 Dominated
§
19 0.73 -0.57 Dominated
§
20 0.68 -1.12 Dominated
§
25 0.59 -2.28 Dominated
§
28 0.60 -2.22 Dominated
§
ICER: incremental cost-effectiveness ratio; HSCT: hematopoietic stem cell
transplantation; BT-ICT: blood transfusion combined with subcutaneous iron
chelating therapy; THB: Thai baht (in 2008 value); and QALY: quality adjusted
life year.
*ICERs are rounded up to nearest 1,000 THB.
§Negative ICER due to higher effectiveness and lower costs of BT-ICT
compared with HSCT.
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Page 8 of 12Figure 3 Tornado diagram. The diagram shows the percentage change in the ICER attributable to the change of each individual parameter.
The numbers at each end of the bars indicate the most extreme values used in the sensitivity analysis. ICER: incremental cost-effectiveness ratio;
THB: Thai baht (in 2008 value); QALY: quality adjusted life year; HSCT: hematopoietic stem cell transplantation; and BT-ICT: blood transfusion
combined with subcutaneous iron chelating therapy.
Figure 4 Cost-effectiveness acceptability curve for related HSCT compared with BT-ICT. These graphs demonstrate the probabilities of
each intervention being cost-effective at different ceiling ratios, classified by age (year) at the start of treatment. (A) Patient aged 1 year, (B)
Patient aged 10 years, (C) Patient aged 15 years, and (D) Patient aged 17 years. Dashed lines represent the willingness to pay thresholds for the
adoption of health interventions in Thailand. BT-ICT: blood transfusion combined with subcutaneous iron chelating therapy; HSCT: hematopoietic
stem cell transplantation; QALY: quality adjusted life year; and THB: Thai baht.
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Page 9 of 12available infrastructure and human resources, especially
hematologists. If the Thai government were to provide
additional budget to significantly expand HSCT services,
it is likely that the cost-per case would fall due to
economies of scale, improving the cost-effectiveness of
HSCT. Such a scenario was considered unlikely in the
near future therefore to ensure the relevance of the ana-
lysis to current policy making needs, the restriction to
200 patients a year was left in place. This restriction
raises further equity concerns in deciding how to allo-
cate these treatments.
Previous published studies suggested that allogeneic
stem cell transplantation was more effective amongst
younger severe thalassemic patients, as older patients
had poorer outcomes and higher transplant-related mor-
tality [29,30]. This could be explained by the fact that
older thalassemic patients had more progressive disease
and prolonged iron overload having received blood
transfusions for a longer period of time [6]. This study
also showed that the QALY gained among younger
HSCT patients was higher than older ones.
This study had several limitations. First, due to the
lack of survival data for patients treated with blood
transfusions in Thailand, their transition probabilities
were based on survival analysis studies in Iran [21-23].
The prevalence of thalassemia and its treatment in
Iran were found to be similar to that of Thailand, in
that severe thalassemia in Iran was the most prevalent
genetic disease and its standard therapy was the provi-
sion of BT-ICT. Likewise, the survival data and transi-
tion probabilities for HSCT patients were obtained
from a relatively small cohort;t h i sa r e ai sap r i o r i t yf o r
Figure 5 Cost-effectiveness acceptability curve for unrelated HSCT compared with BT-ICT. These graphs demonstrate the probabilities of
each intervention being cost-effective at different ceiling ratios, classified by age (year) at the start of treatment. (A) Patient aged 1 year, and (B)
Patient aged 10 years. Dashed lines represent the willingness to pay thresholds for the adoption of health interventions in Thailand. BT-ICT:
blood transfusion combined with subcutaneous iron chelating therapy; HSCT: hematopoietic stem cell transplantation; QALY: quality adjusted life
year; and THB: Thai baht.
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Page 10 of 12future research. Second, the direct medical costs of the
interventions were obtained from different sources.
While both sources originate in the Thai context, the
costs of blood transfusions were derived from a cost of
illness study in three treatment centers in Thailand [4]
whereas the costs of HSCT were estimated from a hos-
pital database. Using a single hospital database could
however underestimate the true costs of blood transfu-
sions, as patients might receive these in a number of
different hospitals. HSCT patients on the other hand,
need to be followed up regularly at the same hospital
so all costs could be collected in a single hospital data-
base. Third, the sensitivity analysis indicated that the
ICER per QALY gained was most sensitive to changes
in the utility of BT-ICT patients which this study
obtained from foreign data (i.e. Australia and UK).
This is identified as an area where further studies
using local data are needed. Fourth, no estimates were
available for the utility parameter of patients receiving
HSCT, so that the utility of HSCT patients with malig-
nant diseases was used instead [26]. Lastly, the utilities
for all HSCT states were similar even though previous
studies revealed that the QoL in the early post HSCT
states would be poor due to possible complications (e.
g. graft-versus-host-disease, infection, and graft failure);
in subsequent states QoL was closer to the norm and
better than patients receiving blood transfusions
[6,30-32].
Conclusions
The results of this study were twice presented to the
Subcommittee for Development of the Health Benefit
Package and Service Delivery of the NHSO. Although
the analysis found that related HSCT for patients aged
less than 10 years was the most cost-effective option in
the Thai context, the currently limited infrastructure
implies that this will only be available to a minority of
patients, proving to be a major obstacle to policy formu-
lation and implementation. This is indicative of a
broader problem that is particularly acute in low and
middle income countries, where life-saving and cost-
effective technologies are becoming more readily acces-
sible while the infrastructure and financial resources are
not yet available to provide these on a large scale and in
an equitable manner. There are immense challenges to
rationing such services in deciding whether these should
be allocated based on a “first come first serve”, “severity
of disease”, “fair inning” or a “lottery principle” [33]. As
a result, the Subcommittee has not reached a consensus
and provided any policy recommendations to the
NHSO. This situation reiterates that economic analysis
alone is insufficient in providing practical decision
recommendations to policy makers where such perti-
nent equity concerns are present. There is an urgent
need to carefully consider social, ethical and moral
dimensions of this health technology beyond its immedi-
ate economic benefits.
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Table 4 Estimated budget impact during fiscal years
2008 to 2022 of provision of HSCT to 200 severe
thalassemic patients (aged 1-10) per year
Estimated budget impact (million THB) Incremental budget
Fiscal year BT-ICT Related HSCT
2008 7 98 91
2009 14 104 90
2010 20 103 83
2011 26 102 76
2012 32 101 69
2013 37 100 63
2014 42 99 57
2015 46 99 53
2016 50 98 48
2017 54 97 43
2018 58 96 38
2019 61 95 34
2020 64 93 29
2021 67 92 25
2022 69 91 22
Total 647 1,468 821
BT-ICT: blood transfusion combined with subcutaneous iron chelating therapy;
HSCT: hematopoietic stem cell transplantation; and THB: Thai baht (in 2008
value).
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